Diabetes Care, Vol 21, Issue 4 649-654, Copyright © 1998 by American Diabetes Association

ARTICLES

Plasma fibrinogen: a new factor of the metabolic syndrome. A population-based study

G Imperatore, G Riccardi, C Iovine, AA Rivellese and O Vaccaro
Department of Clinical and Experimental Medicine, Federico II University, Naples, Italy.

OBJECTIVE: To evaluate whether hyperfibrinogenemia represents a component of the metabolic syndrome. RESEARCH DESIGN AND METHODS: A cross-sectional study was conducted on the relation between fibrinogen and the metabolic syndrome in a working population of 1,252 nondiabetic men, aged 35-64 years, randomly selected among all men participating in a health screening. We measured anthropometric characteristics, blood pressure, fasting plasma fibrinogen, cholesterol (total, LDL, and HDL), triglycerides, glucose, and insulin. Individuals with two or more metabolic abnormalities (defined as being in the highest quartile of the distribution of diastolic blood pressure, plasma glucose, or triglycerides or being in the lowest quartile of HDL cholesterol) were considered to have the metabolic syndrome. RESULTS: Age-adjusted fibrinogen levels correlated significantly with BMI, waist-to-hip ratio, systolic and diastolic blood pressure, plasma total cholesterol, LDL cholesterol, triglycerides, insulin, and HDL cholesterol (inversely). Subjects with the metabolic syndrome had significantly higher plasma fibrinogen levels than those without (285.1 +/- 1.9 vs. 300.2 +/- 3.0 mg/dl, mean +/- SE, P = 0.0001). Plasma fibrinogen concentrations and the prevalence of hyperfibrinogenemia (defined as > or = 350 mg/dl) increased progressively from 279 to 307 mg/dl (P = 0.0001) and from 9 to 22% (P = 0.0024), respectively, across categories with an increasing number of metabolic disorders characterizing the syndrome (only one, any two, three or more). In multivariate analyses, both plasma insulin and the metabolic syndrome were significantly and independently associated with plasma fibrinogen. CONCLUSIONS: The finding suggests that hyperfibrinogenemia may be considered a component of the metabolic syndrome. This may also explain the increased cardiovascular risk associated with hyperinsulinemia/insulin resistance.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				C. Ay, T. Tengler, R. Vormittag, R. Simanek, W. Dorda, T. Vukovich, and I. Pabinger Venous thromboembolism a manifestation of the metabolic syndrome Haematologica, March 1, 2007; 92(3): 374 - 380. [Abstract] [Full Text] [PDF]

				E. Corrado, M. Rizzo, R. Tantillo, I. Muratori, F. Bonura, G. Vitale, and S. Novo Markers of Inflammation and Infection Influence the Outcome of Patients With Baseline Asymptomatic Carotid Lesions: A 5-Year Follow-Up Study Stroke, February 1, 2006; 37(2): 482 - 486. [Abstract] [Full Text] [PDF]

				R. Kahn, J. Buse, E. Ferrannini, and M. Stern The Metabolic Syndrome: Time for a Critical Appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care, September 1, 2005; 28(9): 2289 - 2304. [Abstract] [Full Text] [PDF]

				J. Chen, R. P. Wildman, L. L. Hamm, P. Muntner, K. Reynolds, P. K. Whelton, and J. He Association Between Inflammation and Insulin Resistance in U.S. Nondiabetic Adults: Results from the Third National Health and Nutrition Examination Survey Diabetes Care, December 1, 2004; 27(12): 2960 - 2965. [Abstract] [Full Text] [PDF]

				S. S. Daskalopoulou, D. P. Mikhailidis, and M. Elisaf Prevention and Treatment of the Metabolic Syndrome Angiology, November 1, 2004; 55(6): 589 - 612. [Abstract] [PDF]

				S. S. Daskalopoulou, D. P. Mikhailidis, and M. Elisaf Prevention and Treatment of the Metabolic Syndrome Angiology, November 1, 2004; 55(6): 589 - 612. [Abstract] [PDF]

				V. R. Aroda and R. R. Henry Thiazolidinediones: Potential Link Between Insulin Resistance and Cardiovascular Disease Diabetes Spectr, April 1, 2003; 16(2): 120 - 125. [Abstract] [Full Text] [PDF]

				W. N. Kernan, S. E. Inzucchi, C. M. Viscoli, L. M. Brass, D. M. Bravata, and R. I. Horwitz Insulin resistance and risk for stroke Neurology, September 24, 2002; 59(6): 809 - 815. [Abstract] [Full Text] [PDF]

				N. V. Chu, A. P. S. Kong, D. D. Kim, D. Armstrong, S. Baxi, R. Deutsch, M. Caulfield, S. R. Mudaliar, R. Reitz, R. R. Henry, et al. Differential Effects of Metformin and Troglitazone on Cardiovascular Risk Factors in Patients With Type 2 Diabetes Diabetes Care, March 1, 2002; 25(3): 542 - 549. [Abstract] [Full Text] [PDF]

				A. I. Vinik, T. Erbas, T. S. Park, R. Nolan, and G. L. Pittenger Platelet Dysfunction in Type 2 Diabetes Diabetes Care, August 1, 2001; 24(8): 1476 - 1485. [Abstract] [Full Text] [PDF]

				R. R. Henry Preventing Cardiovascular Complications of Type 2 Diabetes: Focus on Lipid Management Clin. Diabetes, July 1, 2001; 19(3): 113 - 120. [Abstract] [Full Text] [PDF]

				M. Pyorala, H. Miettinen, P. Halonen, M. Laakso, and K. Pyorala Insulin Resistance Syndrome Predicts the Risk of Coronary Heart Disease and Stroke in Healthy Middle-Aged Men : The 22-Year Follow-Up Results of the Helsinki Policemen Study Arterioscler. Thromb. Vasc. Biol., February 1, 2000; 20(2): 538 - 544. [Abstract] [Full Text] [PDF]

				S. M. Grundy, I. J. Benjamin, G. L. Burke, A. Chait, R. H. Eckel, B. V. Howard, W. Mitch, S. C. Smith Jr, and J. R. Sowers Diabetes and Cardiovascular Disease : A Statement for Healthcare Professionals From the American Heart Association Circulation, September 7, 1999; 100(10): 1134 - 1146. [Full Text] [PDF]